Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Increased STAT5/STAT3 Intracellular Signaling in Circulating CD34+ Cells of Patients with PMF Correlates with Disease Severity

Carlotta Abbà, MSc, Rita Campanelli, Paolo Catarsi, Laura Villani, Vittorio Abbonante, PhD, Christian Andrea Di Buduo, PhD, Melania Antonietta Sesta, Vittorio Rosti, MD, Giovanni Barosi, MD, Margherita Massa

Blood (2018) 132 (Supplement 1): 4337.

https://doi.org/10.1182/blood-2018-99-114684

Published: 2018

Journal Articles

EDA Fibronectin-TLR4 Axis Sustains Megakaryocyte Expansion and Inflammation during Bone Marrow Fibrosis Progression

Alessandro Malara, PhD, Cristian Gruppi, PhD, Vittorio Abbonante, PhD, Daniele Cattaneo, MD, Luigi De Marco, MD, Alessandra Iurlo, Umberto Gianelli, MD, Andrés F Muro, PhD, Anil K Chauhan, PhD, Vittorio Rosti, MD, Giovanni Barosi, MD, Alessandra Balduini, MD

Blood (2018) 132 (Supplement 1): 1781.

https://doi.org/10.1182/blood-2018-99-116454

Published: 2018

Journal Articles

Abnormal Regulation of Intracellular Calcium in Human Megakaryocytes Contributes to the Pathophysiology of Calr-Mutant Myeloproliferative Neoplasms

Christian Andrea Di Buduo, PhD, Vittorio Abbonante, PhD, Elisa Rumi, MD, Daniela Pietra, PhD, Francesco Moccia, PhD, Giovanni Barosi, MD, Vittorio Rosti, MD, Mario Cazzola, Alessandra Balduini, MD

Blood (2018) 132 (Supplement 1): 1782.

https://doi.org/10.1182/blood-2018-99-116166

Published: 2018

Journal Articles

PARP Inhibitor Veliparib and Busulfan in a Xenograft Model of Myeloproliferative Neoplasm

Pritesh Patel, MD, Vitalyi Senyuk, PhD, Natalie S. Rodriguez, MS, Dolores Mahmud, PhD, Annie Lee Oh, MD, Nadim Mahmud, MBBS, PhD, Giovanni Barosi, MD, Damiano Rondelli, MD

Blood (2018) 132 (Supplement 1): 3319.

https://doi.org/10.1182/blood-2018-99-119497

Published: 2018

Journal Articles

RUNX1 Expression Characterizes the Endothelial Cells from the Spleen and Bone Marrow of Patients with Primary Myelofibrosis

Rita Campanelli, Margherita Massa, Laura Villani, Paolo Catarsi, Carlotta Abbà, MSc, Elisabetta Dejana, Monica Corada, Federica Pisati, Giovanni Barosi, MD, Vittorio Rosti, MD

Blood (2018) 132 (Supplement 1): 5486.

https://doi.org/10.1182/blood-2018-99-114564

Published: 2018

Journal Articles

Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide

Blood (2018) 132 (Supplement 1): 3037.

https://doi.org/10.1182/blood-2018-99-119402

Published: 2018

Journal Articles

Shared and Tissue-Specific Genetic Features of Primary Myelofibrosis, Hepatic Fibrosis, Idiopathic Pulmonary Fibrosis and Kidney Fibrosis

Anders B Dohlman, MS, Rosa S Kim, Hadassa Hirschfield, Lilian Varricchio, Fiorella Ciaffoni, Massimiliano Dall'ora, Yujin Hoshida, Naftali Kaminski, Giovanni Barosi, MD, Vittorio Rosti, MD, Scott Friedman, Ronald Hoffman, MD, Anna Rita Migliaccio, PhD

Blood (2017) 130 (Supplement 1): 4196.

https://doi.org/10.1182/blood.V130.Suppl_1.4196.4196

Published: 2017

Journal Articles

MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis

Alessandro M. Vannucchi, Paola Guglielmelli, MD PhD, Terra L. Lasho, PhD, Giada Rotunno, MSc, PhD, Carmela Mannarelli, MSc, PhD, Annalisa Pacilli, PhD, Animesh Pardanani, MBBS PhD, Elisa Rumi, MD, Vittorio Rosti, MD, Curtis A. Hanson, MD, Francesco Mannelli, Rhett P. Ketterling, MD, Naseema Gangat, MBBS, Alessandro Rambaldi, MD Prof, Francesco Passamonti, MD, Giovanni Barosi, MD, Tiziano Barbui, MD, Ayalew Tefferi, MD

Blood (2017) 130 (Supplement 1): 200.

https://doi.org/10.1182/blood.V130.Suppl_1.200.200

Published: 2017

Journal Articles

The Role of the Axis TGF-β1/Mir-382-5p/SOD2 in the Induction of Oxidative Stress in CD34+ Hematopoietic Stem/Progenitor Cells from Primary Myelofibrosis

Chiara Rossi, PharmD, Roberta Zini, BSc, PhD, Samantha Ruberti, BSc, PhD, Sebastiano Rontauroli, BSc, Zelia Prudente, BSc, PhD, Greta Barbieri, BSc, Elisa Bianchi, BSc, PhD, Simona Salati, BSc, PhD, Elena Genovese, BSc, Carmela Mannarelli, MSc, PhD, Paola Guglielmelli, MD PhD, Enrico Tagliafico, MDPhD, Vittorio Rosti, MD, Giovanni Barosi, MD, Alessandro M. Vannucchi, Rossella Manfredini, BSc, PhD

Blood (2017) 130 (Supplement 1): 1655.

https://doi.org/10.1182/blood.V130.Suppl_1.1655.1655

Published: 2017

Journal Articles

A Distinct Mutation Profile Might Contribute to the Dismal Outcome of Triple Negative Patients with Primary Myelofibrosis

Blood (2017) 130 (Supplement 1): 1657.

https://doi.org/10.1182/blood.V130.Suppl_1.1657.1657

Published: 2017

Journal Articles

Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy

Holly Geyer, MD, Robyn M. Scherber, MD MPH, Heidi Kosiorek, M.S., Amylou C. Dueck, PhD, Jean-Jacques Kiladjian, MD PhD, Stefanie Slot, Zhijian Xiao, DO, Sonja Zweegman, MD PhD, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernandez-Maraver, PhD, Konstanze Döhner, MD, Claire N. Harrison, Deepti Radia, Pablo J. Muxi, MD, Carlos Besses, Francisco Cervantes, Peter L. Johansson, MD PhD, Bjorn Andreasson, MDPhD, Alessandro Rambaldi, MD, Tiziano Barbui, MD, Karin Bonatz, Andreas Reiter, MD, Francoise Boyer, MD, Gabriel Etienne, MD PhD, Jean-Christophe Ianotto, MD, Dana Ranta, Lydia Roy, MD, Jean-Yves Cahn, Norman I Maldonado, MD, Giovanni Barosi, MD, Maria Ferrari, Robert Peter Gale, MD PhD DSc, Gunnar Birgegard, MD PhD, Zefeng Xu, MD, Yu Zhang, B.S., Xiujuan Sun, MD, Junqing Xu, Peihong Zhang, Peter A. te Boekhorst, Suzan Commandeur, Harry C. Schouten, MD PhD, Heike L Pahl, PhD, Martin Griesshammer, MD, Frank Stegelmann, MD, Thomas Lehmann, Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Jan Samuelsson, MD PhD, Ruben A. Mesa, MD

Blood (2015) 126 (23): 5175.

https://doi.org/10.1182/blood.V126.23.5175.5175

Published: 2015

Journal Articles

Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients

Paola Guglielmelli, MD PhD, Giada Rotunno, Annalisa Pacilli, PhD, Elisa Rumi, MD, Vittorio Rosti, MD, Federica Delaini, MD, Margherita Maffioli, MD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Raimonda Fjerza, MD, Daniela Pietra, PhD, Daniela Cilloni, MD, Francesco Passamonti, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Tiziano Barbui, MD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD

Blood (2015) 126 (23): 351.

https://doi.org/10.1182/blood.V126.23.351.351

Published: 2015

Journal Articles

V617FJAK2-Positive Endothelial Cells Are Present in Bone Marrow Neovessels of Patients with Myelofibrosis and Could Derive from the Transdifferentiation of Mutated Hematopoietic Cells

Laura Villani, BS,, Rita Campanelli, BS, Gabriella Gaudioso, BS, Valentina Poletto, PhD, Elisa Bonetti, PhD, Paolo Catarsi, BS, Gabriela Fois, BS, Benedetta G Erba, PhD, Margherita Massa, PhD, Umberto Magrini, MD, Giovanni Barosi, MD, Umberto Gianelli, MD, Vittorio Rosti, MD

Blood (2015) 126 (23): 2833.

https://doi.org/10.1182/blood.V126.23.2833.2833

Published: 2015

Journal Articles

Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs)

Robyn M. Scherber, MD MPH, Holly Geyer, MD, Claire N. Harrison, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Jean-Jacques Kiladjian, MD PhD, Stefanie Slot, Zhijian Xiao, DO, Sonja Zweegman, MD PhD, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernandez-Maraver, PhD, Konstanze Döhner, MD, Deepti Radia, Pablo J. Muxi, MD, Carlos Besses, Francisco Cervantes, MD PhD, Peter L. Johansson, MD PhD, Bjorn Andreasson, MDPhD, Alessandro Rambaldi, MD, Tiziano Barbui, MD, Karin Bonatz, Andreas Reiter, MD, Francoise Boyer, MD, Gabriel Etienne, MD PhD, Jean-Christophe Ianotto, Dana Ranta, Jean Roy, MD, Jean-Yves Cahn, Norman I Maldonado, MD, Giovanni Barosi, MD, Maria Ferrari, Robert Peter Gale, MD PhD DSc, Gunnar Birgegard, MD PhD, Zefeng Xu, MD, Yu Zhang, B.S., Xiujuan Sun, MD, Junqing Xu, Peihong Zhang, Peter A. te Boekhorst, Suzan Commandeur, Harry C. Schouten, MD PhD, Heike L Pahl, PhD, Martin Griesshammer, MD, Frank Stegelmann, MD, Thomas Lehmann, Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Jan Samuelsson, MD PhD, Ruben A. Mesa, MD

Blood (2015) 126 (23): 4073.

https://doi.org/10.1182/blood.V126.23.4073.4073

Published: 2015

Journal Articles

Reduced Frequency of CD4+CD25++CD127low/-FOXP3+ Regulatory T Cells in Patients with Primary Myelofibrosis

Margherita Massa, PhD, Rita Campanelli, BS, Gabriela Fois, BS, Laura Villani, BS,, Elisa Bonetti, PhD, Paolo Catarsi, BS, Valentina Poletto, PhD, Gianluca Viarengo, MD, Vittorio Rosti, MD, Giovanni Barosi, MD

Blood (2015) 126 (23): 2809.

https://doi.org/10.1182/blood.V126.23.2809.2809

Published: 2015

Journal Articles

Integrative Analysis of Copy Number and Gene Expression Data Suggests Novel Pathogenetic Mechanisms in Primary Myelofibrosis

Blood (2015) 126 (23): 2830.

https://doi.org/10.1182/blood.V126.23.2830.2830

Published: 2015

Journal Articles

Possible Role of Impaired Erk1,2 Phosphorilation and Increased sIL2r Alpha Plasma Levels in the Reduced Frequency of Circulating T Regulatory Cells of Patients with Primary Myelofibrosis

Rita Campanelli, BS, Gabriela Fois, BS, Carlotta Abbà, BS, Mara De Amici, BS, Laura Villani, BS,, Elisa Bonetti, PhD, Paolo Catarsi, BS, Valentina Poletto, PhD, Giovanni Barosi, MD, Vittorio Rosti, MD, Margherita Massa, PhD

Blood (2015) 126 (23): 1639.

https://doi.org/10.1182/blood.V126.23.1639.1639

Published: 2015

Journal Articles

Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm

Blood (2015) 126 (23): 2803.

https://doi.org/10.1182/blood.V126.23.2803.2803

Published: 2015

Journal Articles

What Is the True Response Rate to Ruxolitinib in Persons with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) Needing Therapy for Splenomegaly ?

Giovanni Barosi, MD, Valentina Poletto, Biol Sci, Elisa Bonetti, BS, Laura Villani, Biol Sci, Paolo Catarsi, PhD, Gianluca Viarengo, MD, Rita Campanelli, Biol. Sci, Margherita Massa, PhD, Vittorio Rosti, MD

Blood (2014) 124 (21): 3191.

https://doi.org/10.1182/blood.V124.21.3191.3191

Published: 2014

Journal Articles

A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group

Blood (2014) 124 (21): 3192.

https://doi.org/10.1182/blood.V124.21.3192.3192

Published: 2014

NARROW

Increased STAT5/STAT3 Intracellular Signaling in Circulating CD34+ Cells of Patients with PMF Correlates with Disease Severity

EDA Fibronectin-TLR4 Axis Sustains Megakaryocyte Expansion and Inflammation during Bone Marrow Fibrosis Progression

Abnormal Regulation of Intracellular Calcium in Human Megakaryocytes Contributes to the Pathophysiology of Calr-Mutant Myeloproliferative Neoplasms

PARP Inhibitor Veliparib and Busulfan in a Xenograft Model of Myeloproliferative Neoplasm

RUNX1 Expression Characterizes the Endothelial Cells from the Spleen and Bone Marrow of Patients with Primary Myelofibrosis

Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide

Shared and Tissue-Specific Genetic Features of Primary Myelofibrosis, Hepatic Fibrosis, Idiopathic Pulmonary Fibrosis and Kidney Fibrosis

MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis

The Role of the Axis TGF-β1/Mir-382-5p/SOD2 in the Induction of Oxidative Stress in CD34+ Hematopoietic Stem/Progenitor Cells from Primary Myelofibrosis

A Distinct Mutation Profile Might Contribute to the Dismal Outcome of Triple Negative Patients with Primary Myelofibrosis

Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy

Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients

V617FJAK2-Positive Endothelial Cells Are Present in Bone Marrow Neovessels of Patients with Myelofibrosis and Could Derive from the Transdifferentiation of Mutated Hematopoietic Cells

Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs)

Reduced Frequency of CD4+CD25++CD127low/-FOXP3+ Regulatory T Cells in Patients with Primary Myelofibrosis

Integrative Analysis of Copy Number and Gene Expression Data Suggests Novel Pathogenetic Mechanisms in Primary Myelofibrosis

Possible Role of Impaired Erk1,2 Phosphorilation and Increased sIL2r Alpha Plasma Levels in the Reduced Frequency of Circulating T Regulatory Cells of Patients with Primary Myelofibrosis

Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm

What Is the True Response Rate to Ruxolitinib in Persons with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) Needing Therapy for Splenomegaly ?

A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only